These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22789987)

  • 1. Pharmacology of HIV integrase inhibitors.
    Adams JL; Greener BN; Kashuba AD
    Curr Opin HIV AIDS; 2012 Sep; 7(5):390-400. PubMed ID: 22789987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dolutegravir for the treatment of adult patients with HIV-1 infection.
    Wu G; Abraham T; Saad N
    Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation integrase inhibitors : where to after raltegravir?
    Karmon SL; Markowitz M
    Drugs; 2013 Mar; 73(3):213-28. PubMed ID: 23413196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on raltegravir and the development of new integrase strand transfer inhibitors.
    Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
    South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
    Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
    J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.
    Elliot E; Chirwa M; Boffito M
    Curr Opin Infect Dis; 2017 Feb; 30(1):58-73. PubMed ID: 27798496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reactions to integrase strand transfer inhibitors.
    Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.
    Podany AT; Scarsi KK; Fletcher CV
    Clin Pharmacokinet; 2017 Jan; 56(1):25-40. PubMed ID: 27317415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
    Nguyen B; Foisy MM; Hughes CA
    Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
    Lennox JL
    Curr Opin HIV AIDS; 2012 Sep; 7(5):409-14. PubMed ID: 22789985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.
    van der Galiën R; Ter Heine R; Greupink R; Schalkwijk SJ; van Herwaarden AE; Colbers A; Burger DM
    Clin Pharmacokinet; 2019 Mar; 58(3):309-323. PubMed ID: 29915921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
    Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
    Llibre JM; Montoliu A; Miró JM; Domingo P; Riera M; Tiraboschi J; Curran A; Homar F; Ambrosioni J; Abdulghani N; Force L; Peraire J; Casabona J;
    HIV Med; 2019 Mar; 20(3):237-247. PubMed ID: 30688007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of HIV integrase inhibitors.
    Lee FJ; Carr A
    Curr Opin HIV AIDS; 2012 Sep; 7(5):422-8. PubMed ID: 22886031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.
    Cottrell ML; Hadzic T; Kashuba AD
    Clin Pharmacokinet; 2013 Nov; 52(11):981-94. PubMed ID: 23824675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple choices for HIV therapy with integrase strand transfer inhibitors.
    Raffi F; Wainberg MA
    Retrovirology; 2012 Dec; 9():110. PubMed ID: 23253887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
    d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
    J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of integrase inhibitors in a real-life setting.
    Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
    J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
    Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.